{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:32Z","timestamp":1794047492312,"version":"4.8.0"},"reference-count":37,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) patients have an increased risk of secondary cancers, along with predisposition to CLL in their relatives. We have previously identified germline ATM variants as associated with CLL risk. Here, we present their impact on predisposition to secondary neoplasms in CLL patients and their relatives. Patients enrolled in our tissue bank who had germline ATM status available were mailed a questionnaire between April 2022 and May 2023. Of the 333 patients who replied to the questionnaire, 283 patients (85%) reported at least one relative with a cancer history. The prevalence of family history of B-cell lymphoproliferative disorders was significantly higher (P=0.02) in patients with germline ATM variants (32%) compared to those without germline ATM variants (21%) including familial CLL (25% vs. 18%) (P=0.04). No significant difference in the prevalence of secondary cancers was found between patients with and without germline ATM variants (P=0.73), although the role for individual ATM variants in other malignancies could not be excluded given the small sample size. Time to first CLL treatment (TTFT) was shorter in patients harboring somatic ATM events while no difference was observed in patients with germline ATM variants. In conclusion, we demonstrate a higher prevalence of B-cell lymphoproliferative disorders, including familial CLL, in relatives of CLL patients carrying germline ATM variants. The presence of these germline variants did not impact TTFT compared to patients harboring somatic ATM mutations.<\/jats:p>","DOI":"10.3324\/haematol.2024.286031","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:03:02Z","timestamp":1732186982000},"page":"904-913","source":"Crossref","is-referenced-by-count":3,"title":["Investigating the influence of germline &lt;i&gt;ATM&lt;\/i&gt; variants in chronic lymphocytic leukemia on cancer vulnerability"],"prefix":"10.3324","volume":"110","author":[{"given":"Roberta S.","family":"Azevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomi","family":"Mashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Fardoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Tyekucheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Shupe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Terra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"74139","doi-asserted-by":"crossref","unstructured":"Tsimberidou AM, Wen S, McLaughlin P. Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma. J Clin Oncol. 2009; 27(6):904-910.","DOI":"10.1200\/JCO.2008.17.5398"},{"key":"74140","doi-asserted-by":"crossref","unstructured":"Shen Y, Coyle L, Kerridge I. Second primary malignancies in chronic lymphocytic leukaemia: skin, solid organ, haematological and Richter\u2019s syndrome. EJHaem. 2022; 3(1):129-138.","DOI":"10.1002\/jha2.366"},{"key":"74141","doi-asserted-by":"crossref","unstructured":"Bond DA, Huang Y, Fisher JL. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia. 2020; 34(12):3197-3205.","DOI":"10.1038\/s41375-020-0987-6"},{"key":"74142","doi-asserted-by":"crossref","unstructured":"van der Straten L, Levin MD, Dinnessen MAW. Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Blood Cancer J. 2023; 13(1):15.","DOI":"10.1038\/s41408-023-00784-z"},{"key":"74143","doi-asserted-by":"crossref","unstructured":"Falchi L, Vitale C, Keating MJ. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann Oncol. 2016; 27(6):1100-1106.","DOI":"10.1093\/annonc\/mdw072"},{"key":"74144","doi-asserted-by":"crossref","unstructured":"Eichhorst B, Robak T, Montserrat E. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(1):23-33.","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"74145","doi-asserted-by":"crossref","unstructured":"Benjamini O, Jain P, Trinh L. Second cancers in patients with chronic lymphocytic leukemia who received frontline FCR therapy - distribution and clinical outcomes. Leuk Lymphoma. 2015; 56(6):1643-1650.","DOI":"10.3109\/10428194.2014.957203"},{"key":"74146","doi-asserted-by":"crossref","unstructured":"Santoro A, Rilke F, Franchi F, Monfardini S. Primary malignant neoplasms associated with chronic lymphocytic leukemia. Tumori. 1980; 66(4):431-438.","DOI":"10.1177\/030089168006600404"},{"key":"74147","doi-asserted-by":"crossref","unstructured":"Goldin LR, Bj\u00f6rkholm M, Kristinsson SY, Turesson I, Landgren O. Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin\u2019s lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica. 2009; 94(5):647-653.","DOI":"10.3324\/haematol.2008.003632"},{"key":"74148","doi-asserted-by":"crossref","unstructured":"Brown JR. Inherited predisposition to chronic lymphocytic leukemia. Expert Rev Hematol. 2008; 1(1):51-61.","DOI":"10.1586\/17474086.1.1.51"},{"key":"74149","doi-asserted-by":"crossref","unstructured":"Sud A, Chattopadhyay S, Thomsen H. Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. Blood. 2019; 134(12):960-969.","DOI":"10.1182\/blood.2019001362"},{"key":"74150","doi-asserted-by":"crossref","unstructured":"Goldin LR, Slager SL, Caporaso NE. Familial chronic lymphocytic leukemia. Curr Opin Hematol. 2010; 17(4):350-355.","DOI":"10.1097\/MOH.0b013e328338cd99"},{"key":"74151","doi-asserted-by":"crossref","unstructured":"Berndt SI, Skibola CF, Joseph V. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet. 2013; 45(8):868-876.","DOI":"10.1038\/ng.2652"},{"key":"74152","doi-asserted-by":"crossref","unstructured":"Slager SL, Rabe KG, Achenbach SJ. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood. 2011; 117(6):1911-1916.","DOI":"10.1182\/blood-2010-09-308205"},{"key":"74153","doi-asserted-by":"crossref","unstructured":"Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. Blood. 2006; 108(2):638-644.","DOI":"10.1182\/blood-2005-12-5022"},{"key":"74154","doi-asserted-by":"crossref","unstructured":"Tiao G, Improgo MR, Kasar S. Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia. 2017; 31(10):2244-2247.","DOI":"10.1038\/leu.2017.201"},{"key":"74155","doi-asserted-by":"crossref","unstructured":"Lozanski G, Ruppert AS, Heerema NA. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. Leuk Lymphoma. 2012; 53(9):1743-1748.","DOI":"10.3109\/10428194.2012.668683"},{"key":"74156","doi-asserted-by":"crossref","unstructured":"Austen B, Powell JE, Alvi A. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood. 2005; 106(9):3175-3182.","DOI":"10.1182\/blood-2004-11-4516"},{"key":"74157","doi-asserted-by":"crossref","unstructured":"Austen B, Skowronska A, Baker C. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007; 25(34):5448-5457.","DOI":"10.1200\/JCO.2007.11.2649"},{"key":"74158","doi-asserted-by":"crossref","unstructured":"Stankovic T, Skowronska A. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leuk Lymphoma. 2014; 55(6):1227-1239.","DOI":"10.3109\/10428194.2013.829919"},{"key":"74159","doi-asserted-by":"crossref","unstructured":"Lampson BL, Gupta A, Tyekucheva S. Rare germline ATM variants influence the development of chronic lymphocytic leukemia. J Clin Oncol. 2023; 41(5):1116-1128.","DOI":"10.1200\/JCO.22.00269"},{"key":"74160","doi-asserted-by":"crossref","unstructured":"Thompson D, Duedal S, Kirner J. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005; 97(11):813-822.","DOI":"10.1093\/jnci\/dji141"},{"key":"74161","doi-asserted-by":"crossref","unstructured":"Stucci LS, Intern\u00f2 V, Tucci M. The ATM gene in breast cancer: its relevance in clinical practice. Genes (Basel). 2021; 12(5):727.","DOI":"10.3390\/genes12050727"},{"key":"74162","doi-asserted-by":"crossref","unstructured":"Ji X, Mukherjee S, Landi MT. Protein-altering germline mutations implicate novel genes related to lung cancer development. Nat Commun. 2020; 11(1):2220.","DOI":"10.1038\/s41467-020-15905-6"},{"key":"74163","doi-asserted-by":"crossref","unstructured":"Liu Y, Xia J, Mckay J. Rare deleterious germline variants and risk of lung cancer. NPJ Precis Oncol. 2021; 5(1):12.","DOI":"10.1038\/s41698-021-00146-7"},{"key":"74164","doi-asserted-by":"crossref","unstructured":"Borja NA, Silva-Smith R, Huang M, Parekh DJ, Sussman D, Tekin M. Atypical ATMs: broadening the phenotypic spectrum of ATM-associated hereditary cancer. Front Oncol. 2023; 13:1068110.","DOI":"10.3389\/fonc.2023.1068110"},{"key":"74165","doi-asserted-by":"crossref","unstructured":"Hallek M, Cheson BD, Catovsky D. Special Report iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25):2745-2760.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"74166","unstructured":"UNSD - Methodology. 2023."},{"key":"74167","unstructured":"The jamovi project. jamovi (Version 2.3) [Computer Software]. 2023."},{"key":"74168","doi-asserted-by":"crossref","unstructured":"Richards S, Aziz N, Bale S. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-424.","DOI":"10.1038\/gim.2015.30"},{"key":"74169","doi-asserted-by":"crossref","unstructured":"Kopanos C, Tsiolkas V, Kouris A. VarSome: the human genomic variant search engine. Bioinformatics. 2019; 35(11):1978-1980.","DOI":"10.1093\/bioinformatics\/bty897"},{"key":"74170","doi-asserted-by":"crossref","unstructured":"van Os NJH, Roeleveld N, Weemaes CMR. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet. 2016; 90(2):105-117.","DOI":"10.1111\/cge.12710"},{"key":"74171","doi-asserted-by":"crossref","unstructured":"Thompson D, Duedal S, Kirner J. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005; 97(11):813-822.","DOI":"10.1093\/jnci\/dji141"},{"key":"74172","doi-asserted-by":"crossref","unstructured":"Hall MJ, Bernhisel R, Hughes E. Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Cancer Prev Res (Phila). 2021; 14(4):433-440.","DOI":"10.1158\/1940-6207.CAPR-20-0448"},{"key":"74173","doi-asserted-by":"crossref","unstructured":"Zada M, Lerner D, Piltz Y, Perry C, Avivi I, Herishanu Y. Familial chronic lymphocytic leukemia in Israel: a disproportionate distribution among Ashkenazi Jews. Eur J Haematol. 2017; 99(1):51-55.","DOI":"10.1111\/ejh.12889"},{"key":"74174","doi-asserted-by":"crossref","unstructured":"Stankovic T, Skowronska A. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leuk Lymphoma. 2014; 55(6):1227-1239.","DOI":"10.3109\/10428194.2013.829919"},{"key":"74175","doi-asserted-by":"crossref","unstructured":"Gui\u00e8ze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015; 126(4):445.","DOI":"10.1182\/blood-2015-02-585042"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11837\/77797","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11837\/78239","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11837\/77797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:41Z","timestamp":1794046061000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286031","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}